Summary
Guardant Health, Inc. (GH) has filed an 8-K report detailing an amendment to its material definitive agreement with Illumina, Inc. This amendment, effective January 1, 2021, significantly extends the term of their existing Supply Agreement. The agreement, originally dated September 15, 2014, is crucial as Illumina provides Guardant Health with essential products and services, including sequencers, equipment, and materials used in its laboratory operations for research and clinical activities.
Key Highlights
- 1Guardant Health amended its Supply Agreement with Illumina, Inc.
- 2The amendment extends the supply agreement term to January 2033.
- 3The agreement includes provisions for automatic one-year renewals after January 2033, unless terminated or non-renewal notice is given.
- 4Guardant Health retains the right to terminate the agreement for convenience with 90 days' prior written notice.
- 5The amendment updates the list of specific hardware and consumables provided by Illumina, along with associated pricing terms.
Frequently Asked Questions
The amendment extends the critical supply agreement with Illumina, a key provider of sequencers, equipment, and materials, out to January 2033. This provides Guardant Health with long-term supply chain visibility and stability for its laboratory operations.
Yes, Guardant Health can terminate the Supply Agreement for convenience by providing 90 days' prior written notice. This offers flexibility should the company's strategic needs change.
The amendment updates the specific hardware and consumables to be provided by Illumina and includes revised pricing terms. Investors should look for more details in the upcoming 10-K filing to understand the potential financial impact of these pricing adjustments.